Anacor Pharmaceuticals announced today that David Perry, the company’s Chief Executive Officer, will provide a company overview at the Deutsche Bank Annual Health Care Conference on Monday May 7, 2012 at 4:10 p.m. ET in Boston, Massachusetts.
The event will be webcast live and may be accessed under “Events and Presentations” on the Investors page of Anacor’s website at www.anacor.com. A replay will also be available for three months following the presentation.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered seven compounds that are currently in development including its lead compounds: tavaborole, a topical antifungal for the treatment of onychomycosis; AN2728 a topical anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis; GSK ‘052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which is licensed to GlaxoSmithKline under the companies’ research and development agreement; AN8194, which is licensed to Eli Lilly and Company for an undisclosed animal health application; and AN5568, which is licensed to Drugs for Neglected Diseases initiative for sleeping sickness. Anacor is also developing AN2718 and AN2898 as backups to tavaborole and AN2728, respectively. In addition, Anacor has a research and development agreement with Medicis Pharmaceuticals to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne. For more information, visit http://www.anacor.com.